On May 7, 2025, the OMEGA Study Group hosted the world's first international symposium on once-weekly glycated albumin monitoring. The event brought together 60 participants, including 15 speakers and 13 poster presenters. Attendees represented a wide range of sectors, including physicians and researchers, patient advocacy groups, government officials, national funding agencies such as JST, NEDO, and AMED, healthcare-related companies, and both public and private investors.
Throughout the day, lively discussions were held on the potential of this novel method of glucose monitoring—once-weekly glycated albumin.
This meeting was partially supported by NEDO.
📒Index
Koshin Sekimizu, PhD – President and CEO, Provigate, Inc.
An opening address was delivered by Dr. Koshin Sekimizu (Provigate, Inc.), a board member of the OMEGA Study Group.
We were pleased to welcome many participants, including guests from overseas, from the early morning session.
💺Chair: Koshin Sekimizu, PhD
Keiko Yasukawa, PhD – The University of Tokyo Hospital
The first speaker in the morning seminar was Dr. Keiko Yasukawa (The University of Tokyo Hospital), formerly of Asahi Kasei, who played a key role in the standardization and commercialization of glycated albumin. Dr. Yasukawa shared the history of glycated albumin’s clinical development, dating back to the 1980s.